Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals Inc (NASDAQ: ALNA) today and set a price target of $38. The company’s shares closed yesterday at $13.43.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.6% and a 45.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Miragen Therapeutics Inc.
Allena Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $40.83.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.56 and a one-year low of $6.13. Currently, Allena Pharmaceuticals Inc has an average volume of 124.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.
